HLB BioStep Co

HLB BioStep Co Debt

The Debt of HLB BioStep Co (278650.KQ) as of Nov 5, 2026 is 1.79 B KRW. In the previous year, Debt was 7.16 B KRW — a change of -74.93% (lower).

Debt

1.79 BKRW

YoY

-74.93%

Last updated:

In 2025, HLB BioStep Co's total debt was 1.79 B KRW, a -74.93% change from the 7.16 B KRW total debt recorded in the previous year.

The HLB BioStep Co Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
7.75 B KRW
Jan 1, 2019
6.47 B KRW
Jan 1, 2020
3.81 B KRW
Jan 1, 2021
12.46 B KRW
Jan 1, 2022
88.02 B KRW
Jan 1, 2023
4.19 B KRW
Jan 1, 2024
7.16 B KRW
Jan 1, 2025
1.79 B KRW
The HLB BioStep Co Debt history
YEARDebtYoY
1.79 BKRW-74.93%
7.16 BKRW+70.69%
4.19 BKRW-95.23%
88.02 BKRW+606.29%
12.46 BKRW+227.09%
3.81 BKRW-41.09%
6.47 BKRW-16.59%
7.75 BKRW+14.82%
6.75 BKRW+184.74%
2.37 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

HLB BioStep Co Stock analysis

What does HLB BioStep Co do? HLB bioStep Co., Ltd. generates revenue through three business segments. The Non-clinical Test Consignment Agency Business segment provides testing for new drugs and evaluates efficacy, pharmacodynamics, and safety of substances. The Bioinfra Business segment designs, constructs, and maintains animal laboratories while delivering equipment. The Pet Medical Business segment develops veterinary medicine and sells companion animal products. Clients include pharmaceutical companies requiring non-clinical testing, research institutions needing laboratory infrastructure, and pet care providers purchasing animal health products. The company's Non-clinical Test Consignment Agency Business serves pharmaceutical firms seeking pre-market substance evaluation. Bioinfra Business targets institutions requiring specialized animal lab facilities and equipment. Pet Medical Business supplies veterinary medicine to pet health markets. Revenue streams are derived from testing fees, laboratory services, equipment sales, and product distribution. HLB bioStep's segments align with pharmaceutical development cycles, animal research infrastructure needs, and companion animal healthcare demands. Testing services are contracted by drug developers, lab construction by research organizations, and veterinary products sold to pet care retailers. The company monetizes expertise in non-clinical testing, lab management, and veterinary product distribution without direct consumer sales. HLB BioStep Co is one of the most popular companies on Eulerpool.

Debt Details

Understanding HLB BioStep Co's Debt Structure

HLB BioStep Co's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing HLB BioStep Co's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to HLB BioStep Co’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in HLB BioStep Co’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about HLB BioStep Co stock

Debt of HLB BioStep Co is 1.79 B KRW in 2025.

Debt of HLB BioStep Co changed from 7.16 B KRW to 1.79 B KRW, representing a -74.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt HLB BioStep Co since 2006 – with annual values, charts, and detailed analysis.

Debt's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's HLB BioStep Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — HLB BioStep Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — HLB BioStep Co